• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inhibikase Therapeutics Inc (NQ: IKT )

    2.640 +0.110 (+4.35%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Inhibikase Therapeutics Inc

    < Previous 1 2 3 4 5 Next >
    Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Dow Surges 350 Points; US Crude Oil Stocks Increase
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August
    Via Benzinga
    Exposures Fossil Fuels
    Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today
    Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing. 
    Via Benzinga
    Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024
    IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
    Company to host conference call on August 15, 2024 at 8:00 a.m. ET 
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
    Company expects to report trial results in 4Q24 
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
    From Inhibikase Therapeutics
    Via GlobeNewswire
    IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024
    IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
    Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET 
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
    Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension 
    From Inhibikase Therapeutics
    Via GlobeNewswire
    IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023
    IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
    Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET 
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
    From Inhibikase Therapeutics
    Via GlobeNewswire
    HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
    Via Benzinga
    Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
    Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate 
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
    - The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease - 
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.